Cardiovascular Drugs Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

Mar 2018| TMR281A| Transparency

Report Highlights

Global Cardiovascular Drugs Market: Overview

Cardiovascular drugs are widely used for treating various heart related dysfunction. With increasing number of cardiovascular diseases across the globe is the major driving factor for the growth of the cardiovascular diseases. According to the study conducted by Global Burden of Diseases estimate that the death rate due to CVD is 235 per 100000 in global population. According to WHO, cardiovascular diseases account for 31% deaths globally which is approximately 17.7 million individuals. Out of these 80% of the CVD deaths are due to stroke and heart attacks.  Factors such as sedentary lifestyle, excess consumption of alcohol, stress, unhealthy eating habits, smoking are all factors responsible for the increase in the number of cardiovascular disorders among young population too.

The global cardiovascular drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drug class, indication, distribution channel and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global cardiovascular drugs market.

Global Cardiovascular Drugs Market: Key Segments

Based on drug class the global cardiovascular drugs market is segmented into renin-angiotensin system blockers, beta blockers, diuretics, anti-clotting agents (anti-coagulants and platelet aggregation inhibitors), antihyperlipidemics, other antihypertensive, calcium channel blockers and others. The renin-angiotensin system blockers segment is further classified into ACE inhibitors and angiotensin receptor blockers and the anti-clotting agents segment is further segmented into anti-coagulants and platelet aggregation inhibitors. The drug class segments have been analyzed based on incidence of diseases, awareness regarding early diagnosis and presence of key players in the region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

According to indication the global cardiovascular drugs market is segmented into hypertension, hyperlipidemia, coronary artery diseases, peripheral artery disease, arrhythmia and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Cardiovascular Drugs Market: Regional Outlook

Geographically, the global cardiovascular drugs market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East & Africa (South Africa, GCC Region, Israel and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the cardiovascular drugs market are AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson, Astellas Pharma, Inc., Eli Lilly and Company, Otsuka Holdings Co., Ltd., Takeda Pharmaceuticals Company Limited and others.

The global cardiovascular drugs market has been segmented as follows:

Cardiovascular Drugs Market, by Drug Class

Renin-Angiotensin System Blockers
ACE Inhibitors
Angiotensin Receptor Blockers
Beta Blockers
Diuretics
Anti-Clotting Agents
Anti-Coagulants
Platelet Aggregation Inhibitors
Antihyperlipidemics
Other Antihypertensive
Calcium Channel Blockers
Others

Cardiovascular Drugs Market, by Indication

Hypertension
Hyperlipidemia
Coronary Artery Disease
Peripheral Artery Disease
Arrhythmia
Others

Cardiovascular Drugs Market, by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Cardiovascular Drugs Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
South Africa
GCC Region
Israel
Rest of Middle East & Africa

  • Table 1 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 2 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Renin-Angiotensin System Blockers, 2015–2025
  • Table 3 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class – Anti-Clotting Agents, 2015–2025
  • Table 4 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 5 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 6 : Global Cardiovascular Drugs Market Size (US$ Bn) Forecast, by Region, 2017–2025
  • Table 7 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Table 8 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 9 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
  • Table 10 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
  • Table 11 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 12 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
  • Table 13 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Table 14 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 15 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
  • Table 16 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
  • Table 17 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 18 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
  • Table 19 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Table 20 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 21 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
  • Table 22 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
  • Table 23 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 24 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
  • Table 25 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Table 26 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 27 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
  • Table 28 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
  • Table 29 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 30 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
  • Table 31 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Table 32 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
  • Table 33 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Renin-Angiotensin System Blockers, 2015–2025
  • Table 34 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Anti-clotting Agents, 2015–2025
  • Table 35 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2015–2025
  • Table 36 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2025
  • Table 37 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2025
  • Figure 1 : Global Cardiovascular Drugs Market Snapshot
  • Figure 2 : Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 3 : Global Cardiovascular Market Value Share, by Drug Class (2016)
  • Figure 4 : Global Cardiovascular Market Value Share, by Indication (2016)
  • Figure 5 : Global Cardiovascular Market Value Share, by Distribution Channel (2016)
  • Figure 6 : Global Cardiovascular Market Value Share, by Region (2016)
  • Figure 7 : Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2017 and 2025
  • Figure 8 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by RAS Blockers, 2015–2025
  • Figure 9 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2015–2025
  • Figure 10 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Diuretics, 2015–2025
  • Figure 11 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Anti-clotting Agents, 2015–2025
  • Figure 12 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antihyperlipidemics, 2015–2025
  • Figure 13 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Antihypertensive, 2015–2025
  • Figure 14 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Calcium Channel Blockers, 2015–2025
  • Figure 15 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
  • Figure 16 : Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class 2017-2025
  • Figure 17 : Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2017 and 2025
  • Figure 18 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hypertension, 2015–2025
  • Figure 19 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hyperlipidemia, 2015–2025
  • Figure 20 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Coronary Artery Disease, 2015–2025
  • Figure 21 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Peripheral Vascular Disease, 2015–2025
  • Figure 22 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Antiarrhythmic, 2015–2025
  • Figure 23 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2015–2025
  • Figure 24 : Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication 2017-2025
  • Figure 25 : Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2025
  • Figure 26 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
  • Figure 27 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2015–2025
  • Figure 28 : Global Cardiovascular Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
  • Figure 29 : Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel 2017-2025
  • Figure 30 : Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2016 and 2025
  • Figure 31 : Global Cardiovascular Drugs Market Attractiveness Analysis, by Region
  • Figure 32 : North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 33 : North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 34 : North America Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 35 : North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 36 : North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 37 : North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 38 : North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 39 : North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 40 : North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 41 : Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 42 : Europe Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 43 : Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 44 : Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 45 : Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 46 : Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 47 : Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 48 : Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 49 : Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 50 : Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 51 : Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 52 : Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 53 : Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 54 : Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 55 : Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 56 : Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 57 : Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 58 : Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 59 : Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 60 : Latin America Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 61 : Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 62 : Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 63 : Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 64 : Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 65 : Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 66 : Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 67 : Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 68 : Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, 2017–2025
  • Figure 69 : Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country, 2017 and 2025
  • Figure 70 : Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country
  • Figure 71 : Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2016 and 2025
  • Figure 72 : Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2016 and 2025
  • Figure 73 : Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2025
  • Figure 74 : Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class
  • Figure 75 : Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication
  • Figure 76 : Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel
  • Figure 77 : Global Cardiovascular Drugs Market Share Analysis By Company (2016)

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report